Whole Exome Sequencing Identifies a *GH1* Gene Mutation Causing Familial Isolated Growth Hormone Deficiency with Normal Peak Growth Hormone Concentrations

C. Cabrera Salcedo, M. Andrew, L. Tyzinski, V. Hwa, P. Backeljauw and A. Dauber Cincinnati Center for Growth Disorders, Division of Endocrinology Cincinnati Children's Hospital Medical Center



INTRODUCTION

RESULTS

Several pathologic conditions must be considered and ruled out in children with significant short stature.
A large number of such children remain without a definitive diagnosis and are labeled as having idiopathic short stature (ISS).
In a small proportion of the population, short stature is caused by specific genetic variations with large effect.
Familial isolated growth hormone deficiency (IGHD) type II is autosomal dominantly inherited and caused by splice-site mutations and nucleotide substitutions in the *GH1* gene.

Whole Exome Sequencing (WES)

OBJECTIVE

 This study aimed to identify the etiology of short stature in a four-generation family with dominantly inherited short stature.



Figure 1. WES was performed in P1, P2, S1, B1 and GGMM. We identified the pathogenic variant R183H in GH1 which segregated in the affected individuals.





- P2 4 2 0 0 0 0 0 0 30 60 90 120 150 Time (min)

Figure 2. P1 and P2 underwent repeat GH stimulation tests and were found to have delayed peak GH responses. P1 had a peak GH of 15.4 ng/dL, and P2 had a peak GH of 9.9 ng/dL.

CONCLUSIONS

- WES rapidly identified a genetic etiology in this family with dominantly inherited short stature with normal stimulated growth hormone peaks.
- Genetic testing should be strongly considered in cases of familial short stature even when peak stimulated growth hormone concentrations are normal.
- The missense mutation R183H is a well described genetic variant that causes familial IGHD type II. Individuals with this mutation have

CASE PRESENTATION

- P1 presented at 9 years of age for evaluation of proportional short stature (-3 SD).
- Workup revealed low IGF-1 of 27 ng/ml (99 376) and IGFBP-3 of 1260 ng/ml (2769 – 4790).
- Growth hormone stimulation test was normal with a peak concentration of 15.9 ng/ml.
- Initially diagnosed with ISS.
- Strong family history of short stature appeared to follow an autosomal dominant mode of inheritance which prompted further investigation with WES.

The authors have no disclosures or conflicts of interest

releasable GH stores, but GH secretion is impaired resulting in short stature with a broad spectrum of phenotypes.

 It remains unclear whether or not adult patients with this mutation suffer the consequences of adult GH deficiency. We are implementing a protocol to investigate body composition, skeletal integrity, cardiovascular risk profile and the overall quality of life in the affected adults of this kindred.

REFERENCES

- Wajnrajch MP, Gertner JM, Mullis PE, et al. 2000 Arg183His, a new mutational "hot-spot" in the growth hormone (GH) gene causing isolated GH deficiency type II. J. Endocr Genet 1:125–135 - See more at: http://press.endocrine.org/doi/ref/10.1210/jcem.86.8.7723#sthash.NSNeSbwU.dpuf
- Deladoey, J., Stocker, P., & Mullis, P. E. (2001). Autosomal dominant GH deficiency due to an Arg183His GH-1 gene mutation: clinical and molecular evidence of impaired regulated GH secretion. J Clin Endocrinol Metab, 86(8), 3941-3947. doi: 10.1210/jcem.86.8.7723



DOI: 10.3252/pso.eu.55ESPE.2016



